PTC Therapeutics (PTCT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - PTC Therapeutics reported a revenue of $164.68 million for Q4 2025, marking a year-over-year decline of 22.8% and significantly missing the Zacks Consensus Estimate of $304.72 million by 45.96% [1] - The company experienced an EPS of -$1.67, which is a substantial drop from -$0.24 a year ago, resulting in an EPS surprise of -700.58% compared to the consensus estimate of -$0.21 [1] Revenue Breakdown - Net product revenue reached $183.99 million, exceeding the four-analyst average estimate of $174.53 million, reflecting an 18.9% year-over-year increase [4] - Royalty revenue was reported at $79.39 million, surpassing the average estimate of $70.77 million, with a year-over-year change of 36.5% [4] - Net product revenue from Translarna was $39 million, slightly below the average estimate of $40.42 million, showing a significant decline of 58.4% year-over-year [4] - Net product revenue from Emflaza was $27.1 million, which is lower than the estimated $29.58 million, representing a 46.3% decrease compared to the previous year [4] - Collaboration and license revenue was reported at -$0.07 million, a stark contrast to the average estimate of $118.82 million [4] Stock Performance - PTC Therapeutics shares have returned -8.8% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]